AbleDocs Inc. Announces the Acquisition of Diversa Docs ApS to Further Reach of the Worldwide Leader in Document Accessibility Products and Services Throughout Scandinavia
AbleDocs Inc. the leading PDF accessibility product and service provider, and Diversa Docs ApS, a recognized leader in PDF and Web Accessibility services announce their coming together to become the Scandinavian leader in PDF accessibility products and services.
With a long-standing record of collaboration, both companies’ founders and leadership teams couldn’t be more excited to leverage each other’s capabilities to offer their existing and new clients the best in PDF/UA products and services.
“Diversa Docs has consistently been recognized as a leader in excellence in delivering PDF/UA compliant and accessible PDFs, and this acquisition will allow our combined client base to benefit from the experience, and scale of our products and services throughout Scandinavia,” said AbleDocs’ President (GLOBAL), Adam Spencer. “With their amazing team and end user focused approach, they are the ideal partner for AbleDocs. With our combined effort, we can drive the creation of next-generation PDF accessibility services and solutions,” said Vice-President (SCANDINAVIA), Jens Bjerre Kirkegaard.
“Accessibility has always appealed to me because it combines a technical field with a humanistic one,” says CEO of Diversa Docs, Asbjørn Fangel-Hansen.
“Having worked for 12 years in the Danish public sector within accessibility and most recently as the owner of one of the leading companies in the field of accessibility in Denmark, I am very honored to be part of one of the absolute leading global players when it comes to accessible documents,” adds Fangel-Hansen.
The combination of AbleDocs and Diversa Docs will widen the global presence of AbleDocs for products, services, solution development, training, and localized document accessibility support across 49 languages to ensure clients receive the best offerings possible.
About Diversa Docs
Diversa Docs ApS was founded by Lars Holm-Sørensen and Asbjørn Fangel-Hansen in 2019 as a sister company to Diversa ApS. Since then, the company has developed into one of the leaders in Denmark in terms of document accessibility and the area in general.
About AbleDocs Inc.
AbleDocs was founded in 2019 as a conglomerate of PDF accessibility remediation service providers and has grown to have operations in Canada, Denmark, Germany, Switzerland, and the United States. Its founders have been making documents accessible for over 150 years combined experience and has since expanded its offerings to include a completely new approach to document accessibility strategies to include products for high volume document accessibility, document accessibility testing.
AbleDocs is the only company in the world to guarantee the compliance of every file they produce and back it with a $10,000,000 liability guarantee. Current offerings include ADService, ADGateway, ADScan, ADStream, ADLegacy, ADForms, axesWord and axesPDF.
For more information, visit https://www.abledocs.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210406005229/en/
Contact information
For media inquiries:
Gary MacKay, mediainquiries@abledocs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom